Revolution Medicines (RVMD) Common Equity (2018 - 2026)

Revolution Medicines has reported Common Equity for 9 years, with the latest figure at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 27.82% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 27.82% YoY), and the FY2025 full-year result was $1.6 billion, down 27.98% from the prior year.
• Common Equity for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Common Equity was $2.3 billion in Q4 2024, with the low at $498.8 million in Q2 2022.
• Average Common Equity over 5 years is $1.3 billion, with a median of $1.6 billion recorded in 2024.
• Year-over-year, Common Equity surged 166.52% in 2023 and declined 27.98% in 2025.
• Tracing RVMD's Common Equity over 5 years: stood at $685.2 million in 2022, then surged by 166.52% to $1.8 billion in 2023, then gained by 24.04% to $2.3 billion in 2024, then decreased by 27.98% to $1.6 billion in 2025, then declined by 8.05% to $1.5 billion in 2026.
• The last three Common Equity figures came in at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison